Mark Eisenberg
Tel.: 514-340-8222
 
Or contact:
Sarah Windle
514-340-8222

Dr. Mark J. Eisenberg

Senior Investigator, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute
Director of the Cardiovascular Health Services Research Group, Jewish General Hospital
Professor of Medicine, McGill University
 
 
Dr. Eisenberg is a tenured Professor of Medicine at McGill University and a Staff Cardiologist at the Jewish General Hospital. He is the Director of Clinical Research of the McGill Cardiology Fellowship Program and an Associate Member of the McGill Department of Epidemiology, Biostatistics, and Occupational Health. In addition to his clinical responsibilities, Dr. Eisenberg is Director of the McGill MD-PhD Program, as well as Director of the Cardiovascular Health Services Research Group of the Jewish General Hospital and a Principal Investigator at the Centre for Clinical Epidemiology and Community Studies.

Dr. Eisenberg was born in Rochester, New York. He completed a BA in Chemistry in 1980 at Cornell University, followed by an MD at the University of Rochester. After completing his MD, Dr. Eisenberg did a residency in internal medicine at McGill University, a Masters of Public Health at Harvard University, a research fellowship in echocardiography and epidemiology and a cardiology fellowship at the University of California in San Francisco. Finally, in 1995, Dr. Eisenberg completed an interventional cardiology fellowship at the Cleveland Clinic.

In 2008-2009, Dr. Eisenberg spent a year in Israel as a visiting professor in the Department of Human Metabolism and Nutrition at the Joseph H. and Belle R. Braun Hebrew University, Hadassah School of Public Health and Community Medicine. During this sabbatical, he also completed an International Master’s of Health Leadership at McGill University and wrote a book entitled, The Physician-Scientist’s Career Guide (Springer-Humana Press).

Dr. Eisenberg is married and has five children. He is fluent in English, French, and Hebrew.

Major Research Activities

Over the course of his career, Dr. Eisenberg has published over 250 articles in peer-reviewed journals and participated in multiple collaborative works. His research focuses on the primary and secondary prevention of cardiovascular disease, with topics ranging from interventional cardiology to broad public health issues such as smoking and obesity. His research team is examining the use and effectiveness of various smoking cessation pharmacotherapies with several randomized controlled trials. The Zyban as an Effective Smoking Cessation Aid (ZESCA) trial compared the efficacy of bupropion (Zyban) to that of a placebo as a means of reducing smoking rates in patients following an enzyme-positive acute coronary syndrome (ACS). The Evaluation of Varenicline (Champix™) in smokIng cessation for paTients post-Acute coronary syndrome (EVITA) trial examined the efficacy and safety of varenicline for smoking cessation post-ACS. The CIHR-funded Evaluating the Efficacy of E-Cigarette use for Smoking Cessation (E3) Trial is an ongoing randomized controlled trial examining nicotine and non-nicotine e-cigarettes for smoking cessation in the general population of smokers motivated to quit.

Dr. Eisenberg’s research also includes other cardiovascular risk factors, such as obesity and the metabolic syndrome. Among these projects are a meta-analysis of popular diets and a meta-analysis of cardiac outcomes in patients with the metabolic syndrome. The latter project included a systematic review of fibrates and a meta-analysis of the efficacy of weight loss pharmacotherapies. Other projects include a systematic review and meta-analysis of legislative approaches to decreasing obesity and a meta-analysis examining the efficacy and safety of diets, exercise, pharmacotherapies, and surgical interventions for weight loss. Recent systematic reviews and meta-analyses concern the regulation, ethics, and efficacy of e-cigarettes for smoking cessation.

Recent Publications
 
Eisenberg MJ, Windle SB, Roy N, Old W, Grondin F, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, Cassavar D, Dion D, Haught H, Mehta SR, Baril JF, Lambert CR, Madan M, Abramson B, Dehghani P. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. Circulation 2016; 133:21-30.

Mottillo S, Boyle P, Jacobi Cadete LD, Rouleau J-L, Eisenberg MJ. A National Survey of Mentoring Practices for Young Investigators in Circulatory and Respiratory Health. Can Respir J 2016; 2016:5260134.

Franck C, Budlovsky T, Windle SB, Filion KB, Eisenberg MJ. Electronic Cigarettes in North America: History, Use, and Implications for Smoking Cessation. Circulation 2014; 129:1945-52.
Snapshot
Dr. Mark Eisenberg has conducted research related to the technological assessment of cardiac care, medication use for cardiovascular disease, and cost effectiveness.
He conducted the first randomized clinical trial (the ADORE Trial) to compare routine and selective functional testing for the identification of restenosis.

His current focus is on preventative measures for cardiovascular disease, including smoking cessation and weight loss.
 
 
Important Links

McGill University Cardiology Division

McGill University Division of Clinical Epidemiology

 
Support research at the Lady Davis Institute - Jewish General Hospital